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A simple gradient Ultra Performance liquid chromatographic method (UPLC) was developed for 
determination of lopinavir and ritonavir from its related impurities and assay for the ﬁrst time. This method 
involves the use of a C18 (Acquity UPLC BEH C18, 50 × 2.1 mm, 1.7 µm) column thermostated at 30 
oC using triethylamine (pH 2.2): 0.1% H3PO4 in acetonitrile and methanol (85:15) as mobile phase in 
gradient elution mode. A Photo Diode Array (PDA) detector set at 215 nm was used for detection with 
flow rate 0.4 mL/min. This method was validated over the range of limit of quantitation (LOQ) to 50 to 
150% of impurity speciﬁcation limit and of working concentration for assay. The developed method was 
validated for linearity, range, precision, accuracy and speciﬁcity. This method was successfully applied 
for content determination of lopinavir and ritonavir in pharmaceutical formulations. This method can 
be conveniently used in quality control laboratory for routine analysis for assay and related substances 
as well as for evaluation of stability samples of bulk drugs and pharmaceutical formulations.
Uniterms: Lopinavir/determination. Ritonavir/determination.Ultra Performance liquid chromatography/
qualitative analysis.Ultra Performance liquid chromatography/quantitative analysis. Bulk drugs/qualitative 
analysis. Pharmaceutical formulations/qualitative analysis. Pharmaceutical formulations/impurity proﬁle. 
Bulk drugs/impurity proﬁle.
Desenvolveu-se, pela primeira vez, método de cromatograﬁa líquida de ultra-eﬁciência (UPLC), com 
gradiente simples, para a determinação de lopinavir e ritonavir e suas impurezas relativas. Esse método 
envolve o uso de C18 (Acquity UPLC BEH C18, 50 × 2,1 mm, 1,7 µm), termostatizada a 30 oC, utilizando-
se trietilamina (pH 2,2) e fase móvel de H3PO4 0,1% em acetonitrila e metanol (85:15), em eluição por 
gradiente. Detector de arranjo de fotodiiodo (PDA), ﬁxado a 215 nm, foi utilizado para a detecção, 
com fluxo de 0,4 mL/min. Esse método foi validado em faixa de limite de quantiﬁcação (LOQ) de 50 
a 150% de limite de impureza e da concentração de trabalho para o ensaio. O método desenvolvido foi 
validado quanto à linearidade, faixa, precisão, exatidão e especiﬁcidade. Esse método foi aplicado com 
sucesso para a determinação de lopinavir e de ritonavir em formulações farmacêuticas. Tal método pode 
ser convenientemente utilizado em laboratório de controle de qualidade, não só para análise de rotina e 
ensaio de substâncias relacionadas, como também para a avaliação da estabilidade de amostras a granel 
ou em formulações farmacêuticas. 
Unitermos: Lopinavir/determinação. Ritonavir/determinação. Cromatograﬁa Líquida de Ultra Eﬁciência/
análise qualitativa.Cromatograﬁa Líquida de Ultra Eﬁciência/análise quantitativa. Fármacos a granel/
análise qualitativa. Formulações farmacêuticas/análise qualitativa.Formulações farmacêuticas/perﬁl de 
impureza. Fármacos a granel/perﬁl de impureza.
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INTRODUCTION
Lopinavir is an anti-Human immunodeficiency 
virus (HIV) drug which belongs to the class of drugs 
known as protease inhibitors (PIs) (Raffanti, Haas, 2001). 
These drugs block the activity of the HIV protease (or 
proteinase) enzyme to slow HIV replication and delay 
damage to the immune system. Lopinavir is chemically 
designated as [1S-[1R*, (R*), 3R*, 4R*]]-N-[4-[[(2,6-
dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-
(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-
2-oxo-1(2H)-pyrimidineacetamide. Its molecular 
formula is C37H48N4O5, and its molecular weight is 
628.80. Lopinavir was formulated with another protease 
inhibitor, ritonavir. When administered alone, lopinavir 
has insufficient bioavailability. However, like several 
other HIV protease inhibitors, its blood levels are greatly 
increased by low doses of ritonavir, a potent inhibitor of 
cytochrome P450 3A4 (Sham et al., 1998; Kumar et al., 
1999) and therefore lopinavir is co-administered with 
sub-therapeutic doses of ritonavir by oral administration. 
Ritonavir is chemically designated as 10-hydroxy-
2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-
thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-2,4,7,12-
tetraazatridecan-13-oic acid, 5-thiazolylmethyl ester, 
[5S-(5R*,8R*,10R*,11R*)]. Its molecular formula 
is C37H48N6O5S2, and its molecular weight is 720.95. 
Ritonavir (RTV) is a selective, competitive and reversible 
inhibitor of both HIV-1 and HIV-2 proteases. It is widely 
used in the treatment against Acquired immunodeﬁciency 
syndrome (AIDS) and particularly to inhibit liver 
enzyme, viz., cytochrome P450-3A4 (CYP3A) (Yekkala 
et al., 2008). Lopinavir and ritonavir are freely soluble 
in methanol and ethanol; soluble in isopropanol and 
practically insoluble in water. The presence of impurities 
in drugs and drug products should be identiﬁed and 
quantiﬁed to evaluate the safety and efﬁcacy of the drug 
product. In order to do this, the impurities related to the 
drug should be initially evaluated with the established 
threshold levels (ICH 2002). Therefore, it is the primary 
responsibility of an analytical chemist to develop and 
validate the method to meet the requirements of regulatory 
authorities. Effective method development can occur only 
with the cooperation of process chemists, pharmaceutical 
scientists and process engineers, with exhaustive review 
of the literature. Several High Performance Liquid 
Chromatography (HPLC) methods have been described 
in the literature for the determination of lopinavir and 
ritonavir individually (Yekkala et al., 2008; Dias et al., 
2005; Faux et al., 2001). These are for the determination 
of antiretrovirals simultaneously in human plasma by 
Reverse phase-HPLC: Wang et al. (2006), Rentsch, 
(2003), Gangl et al. (2002), and Usami et al., (2003) 
Two High performance liquid chromatography (HPLC) 
methods (Donato et al., 2006; USP, ) and one High 
performance thin layer chromatography (HPTLC) method 
(Sulebhavikar et al., 2008) were reported in the literature 
for determination of lopinavir and ritonavir in soft gelatin 
capsules and were fully validated as per International 
congress Harmonization (ICH) requirements. However, 
HPLC method reported by Donato et al. (2006) was 
restricted to the determination of lopinavir and ritonavir 
only from its degradation products and the details of 
degradation impurities formed under the stress conditions 
employed were not discussed. The literature explained the 
HPLC methods for the determination of related substances 
of lopinavir and ritonavir individually or simultaneously. 
All methods were carried out for long time to get good 
resolution between the impurity peaks. Lopinavir 
impurities (www.usp.org) are:
·	 Impurity-A [chemically N-{1-benzyl-4-[2-(2,6-
dimethyl-phenoxy)-acetylamino]-3-hydroxy-
5-phenyl-pentyl}-2-(2-oxo-tetrahydro-pyrimidin-
1-yl)-propionamide],
·	 Impurity-B [chemically 3-methyl-2-(2-oxo-
tetrahydro-pyrimidin-1-yl)-pentanoic acid{1-
benzyl-4-[2-(2,6-dimethyl-phenoxy)-acetylamino]-
3-hydroxy-5-phenyl-pentyl}amide],
·	 N-acyl impurity [chemically N-{1-benzyl-4[2-(2,6-
dimethyl-phenoxy)-acetylamino]-3-hydroxy-5-phe-
nyl-pentyl}-2-{3-[2-(2,6-dimethyl-phenoxy)-
acetyl]-2-oxo-tetrahydro-pyrimidin-1-yl}-3-methyl-
butyramide],
·	 O-acyl impurity [chemically (2,6-dimethyl-
phenoxy)-aceticacid1-{1-[2-(2,6-dimethyl-
phenoxy)-acetylamino]-2-phenyl-ethyl}-3-[3-
methyl-2-(2-oxo-tetrahydro-pyrimidin-1-yl)-butyryl 
amino]-4-phenyl-butyl ester]
·	 2,6-dimethyl phenoxy acetic acid
Ritonavir impurities (www.usp.org) are:
·	 Impurity-F [chemically 1,3-thiazol-5-yl methyl 
(1S,2S,4S)-2-hydroxy-4-((4S)-4-(1-methylethyl)-
2 ,5-dioxoimidazol id in-1-yl ) -5-phenyl-1-
(phenylmethyl)pentyl)-carbamate],
·	 Impurity-I [chemically 1,3-thiazol-5-yl-methyl-
((1S,2S,4S-4-((2s)-2-(((2-ethyl-1,3-thiazol-4yl)
methyl)(methyl)amino)-carbonyl)amino-3-methyl-
butanoyl)amino)-2-hydroxy-5-phenyl-1-(phenyl-
methyl)pentyl)carbamate,
·	 Impuri ty-L [chemical ly  (2S)-3-methyl-2-
(((methyl((2-(1-methylethyl)-1,3-thiazol-4-yl)
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methyl)amino)carbonyl)amino)-n-((1S)-2-((4S,5S)-
2-oxo-4-(phenylmethyl)-1,3-oxazolidine-5-yl)-1-
(phenylmethyl)ethyl)butanamide].
The aim of this current study was to develop 
and validate a simple gradient UPLC method for 
the determination of process-related impurities and 
degradation products, and to validate it in accordance with 
the ICH guidance document (ICH, 2005). This method 
aimed to resolve the potential impurities and degradants 
of lopinavir and ritonavir.
MATERIAL AND METHODS
Chemicals
HPLC grade ortho phosphoric acid and methanol 
procured from Merck (India) were used. HPLC grade. 
Triethylamine and acetonitrile were procured from 
Spectrochem and Qualigens respectively. HPLC grade 
water obtained from Millipore system (Millipore Inc., 
USA) was used throughout the analysis. Qualiﬁed 
impurity standards and drugs were obtained from Matrix 
Laboratories Limited, Kazhipally, Medak District, India 
and were used without any further puriﬁcation. The water 
used for dilutions and making solutions was obtained 
through the Milli-Q water puriﬁcation system available 
in the laboratory.
UPLC Instrumentation and operating conditions
A Waters, Acquity UPLC (Milford, MA, USA) 
equipped with binary solvent manager, sample manager, 
column heater and photodiode array detector was used. 
UPLC columns used in the present study were: (1) Acquity 
UPLC BEH C8 1.7 µm×2.1 mm x 100 mm; (2) Hypersil 
Gold 1.9 µm×2.1 mm x 50 mm and (3) BEH C18 1.7 
µm×2. 1mm x 50 mm. The column BEH C18 1.7 µm×2.1 
mm x 50 mm was thermostated at 30 oC was used for the 
separation.
Analytical procedure
Methanol was used as diluent in the preparation 
of analytical solutions. Lopinavir, 8 µg/mL and 2 µg/
mL of ritonavir working reference standard solutions 
were prepared using methanol. Weigh 20 tablets of each 
containing 200 mg of lopinavir & 50 mg of ritonavir and 
crush them into powder. An equivalent quantity of powder 
was weighed and dissolved in methanol to get 4 mg/mL 
of lopinavir & 1 mg/mL of ritonavir concentration and 
sonicate for 20 min with occasional shaking. Pass the 
solution through a suitable ﬁlter of 0.22-µm pore size. The 
sample solution was stable for at least 20 hours at room 
temperature. Solutions of all the related substances (0.25 
mg/mL) were prepared by dissolving known amounts of 
the substances initially in 3 mL of methanol and made 
up to the mark with diluent. These solutions were diluted 
further adequately to study the validation attributes. A 
standard solution 8 µg/mL of lopinavir and 2 µg/mL of 
ritonavir was spiked and it was used as system suitability 
solution. The specification limits used for validation 
studies were 0.5% for lopinavir impurities and 0.2% for 
ritonavir impurities with respect to the concentration 
of drug. Reference solution was made according to the 
in-house specification that is 0.2% of lopinavir and 
ritonavir with respect to sample concentration, 0.5% 
of lopinavir impurities (0.02 mg/mL) with respect to 
lopinavir concentration and 0.2% of ritonavir impurities 
(0.002 mg/mL) with respect to ritonavir concentration. 
Reference soluction, 3.5 µL, system suitability solution, 
blank, six replicate injections of diluted standard solution 
and sample solution were separately chromatographed. 
A resolution of not less than 2.5 and tailing factor of not 
more than 1.5 between ritonavir and lopinavir was set 
as system suitability requirement. All the known and 
unknown related substances were determined against 
mean area obtained from replicate injections of diluted 
standard solution.
RESULTS AND DISCUSSION
Method development and separation studies on 
drugs and its impurities
In all UPLC runs, the mobile phase was ﬁltered 
through 0.22 µm nylon membrane and degassed before 
use. The injection volume was 3.5 µL and the analytical 
wavelength was set at 215 nm, which was selected using 
scan mode in photodiode array detector from 200 nm to 
400 nm. The mobile phase flow rate was set at 0.4 mL/
min from 0.25 mL/min, because run time was long at 0.25 
mL/min. Preliminary UPLC analyses were performed 
using an Acquity UPLC BEH C8 1.7 µm×2.1 mm x 100 
mm and Hypersil Gold 1.9 µm×2.1 mm x 50 mm and 
mobile phase composed of various buffers, acetonitrile 
and methanol combinations. In trial and error method, 
base line, resolution, system suitability requirements, 
peak purity, Signal to noise (S/N) ratio and response 
factor did not meet the acceptance criteria. This led to the 
further development of the method to resolve the drug and 
impurities peaks. The mobile phase was then modiﬁed to 
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obtain a ﬁnal composition of the mobile phase at different 
time. The flow rate and injection volumes were 0.4 mL/
min and 3.5 µL respectively. The analysis was carried out 
under gradient conditions as follows, time (min)/A (v/v):B 
(v/v); T0.01/65:35, T3.0/50:50, T5.0/50:50, T10.0/20:80, 
T11.0/65:35 and T12.0/65:35. The data was acquired at 
215 nm for 12 min and processed by use of Empower 
Pro data handling system. The UPLC runs using the 
modiﬁed method ended with the required resolution of 
all peaks along with the good baseline and good signal to 
noise ratio. The ﬁnal method was then optimized with the 
above mobile phase conditions with the use of a BEH C18 
1.7 µm×2.1 mm x 50 mm Column, keeping the column 
temperature at 30 °C. Sample temperature was maintained 
at 5 °C. The degradants were ﬁnally resolved with required 
resolution.
In the ﬁnal method, mobile phase A was prepared 
by dissolving 2 mL of triethylamine in 1000 mL of water 
and pH was adjusted to 2.2±0.05 using orthophosphoric 
acid. 0.1% ortho phosphoric acid in acetonitrile and 
methanol (85:15) was used as mobile phase B. Here, ortho 
phosphoric acid was used to improve the response of peaks 
by decreasing signal to noise ratio; triethylamine was used 
to increase the sharpness of peaks and for good resolution; 
85:15 ratio of mobile phase was used to minimize the time 
of elution of both peaks and to resolve peaks with good 
resolution. Selection of wavelength was based on the 
overlap spectra. Though λmax of drugs and impurities was 
at 210 and 211 nm, due to solvent effect, the wavelength 
was set at 215 nm. Column temperature was set at 30 ºC 
for good baseline and clear separation of all peaks. Sample 
temperature was maintained at 5 °C because of instability 
of drug at room temperature. Laboratory batches of 
reference standard of lopinavir and ritonavir along with 
impurities and the formulation were analyzed using the 
UPLC method. The optimized method expressed that 
all the peaks were eluting with required resolution and 
baseline was good with good signal to noise ratio. All the 
peaks were well distributed throughout the run time. The 
ﬁnal method minimized the Blank interference and was 
optimized by the validation parameters. 
System suitability
From the system suitability studies, resolution 
between ritonavir and lopinavir was 6.56; tailing factor, 
theoretical plate and peak area for lopinavir and ritonavir 
were 1.07&1.05, 57299.87 & 22485.28 and 162956 
& 32209 respectively. The result of system suitability 
satisﬁed the suitability parameters.
Validation parameters
Specificity
A solution of 0.05 mg/mL of lopinavir, 0.05 
mg/mL of ritonavir, 0.5% with respect to lopinavir 
concentration of lopinavir impurities (0.02 mg/mL) and 
0.2% with respect to ritonavir concentration of ritonavir 
impurities (0.002 mg/mL) was prepared and was injected 
individually and as coinjection to check the coelution of 
peaks for speciﬁcity. The resolution between the peaks 
corresponding to impurities and drugs were also studied 
for method speciﬁcity. Figure 1 and Table I demonstrate 
the method of speciﬁcity in which lopinavir, ritonavir and 
its impurities were well resolved with a resolution of more 
than 2.32 and with no interference with the drug peak, 
indicating that the method was selective and speciﬁc for 
its intended use.
Linearity
The linearity of the method was studied with 
different concentrations of 20%, 40%, 60%, 80%, 100%, 
120% and 150% of reference solutions (1.6, 3.2, 4.8, 6.4, 
8.0, 9.6 and 12 µg/mL for lopinavir and 0.4, 0.8, 1.2, 1.6, 
2.0, 2.4 and 3 µg/mL for ritonavir). Each concentration 
was injected in duplicate into UPLC system. Regression 
parameters were summarized for Linearity. The linearity of 
peak areas versus different concentrations was evaluated 
for lopinavir, ritonavir and its impurities using 7 levels 
ranging 20 to 150% with respect to reference solution. 
The linear regression data for all the components tested 
were presented in Table II. The linear data confirmed 
that the detector response at 215 nm was linear over the 
ranges studied for all components. The linearity results 
for lopinavir, ritonavir and their known impurities in the 
speciﬁed concentration range were found satisfactory, with 
a correlation coefﬁcient greater than 0.990.
Limits of detection and quantitation (LOD and 
LOQ)
The quantiﬁcation limit and detection limit of 
impurities and the drug were determined by diluting 
known concentrations of each impurity and drugs until 
signal-to-noise ratios were obtained at about 10:1 and 3:1 
respectively as per ICH guideline. The LOD and LOQ 
values of lopinavir were 0.332 µg/mL and 0.831 µg/mL; 
for ritonavir, 0.488 µg/mL and 1.22 µg/mL; for lopinavir 
impurities, from 0.425 to 1.353 µg/mL; and for ritonavir 
impurities, from 0.785 to 1.24 µg/mL respectively. The 
results were depicted in Table II. The results indicate that 
the method was capable of detecting and quantifying the 
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TABLE I – Speciﬁcity results
S.NO. Component RT (minutes) RRT USP Resolution USP Asymmetry
1 2,6-dimethyl Imp 1.406 0.243 - 1.06
2 Impurity-F 3.047 0.527 20.11 1.04
3 Impurity-I 3.801 0.657 9.70 1.05
4 Impurity-A 4.381 0.758 6.62 1.10
5 Ritonavir 4.871 0.842 4.46 1.11
6 Impurity-L 5.157 0.892 2.32 1.10
7 Lopinavir 5.782 1.000 5.03 1.06
8 Impurity-B 6.668 1.153 8.27 1.09
9 N-Acyl Imp 9.368 1.620 34.15 1.11
10 O-Acyl Imp 9.934 1.718 8.32 1.10
RT= Retention time; RRT = Relative retention time; USP= U.S.Pharmacopeia
FIGURE 1 - Chromatogram of lopinavir, ritonavir and its impurities.
impurities in reliably low concentrations.
Precision
System precision was veriﬁed using diluted standard 
solution, which was analyzed for six times and Percentage 
Relative Standard deviation (%RSD) of lopinavir and 
ritonavir peak areas was evaluated and was found to be 
1.0%. The precision of the method was demonstrated 
using a repeatability test. Repeatability was evaluated by 
measuring the peak responses of six replicate injections. 
The overall %RSD was evaluated and was found to be in 
the range of 0.29–0.64% for all related substances, which 
were within the acceptance criterion of Not more than 
(NMT) 10.0% RSD. The results are presented in Table III.
Accuracy (recovery)
Accuracy of the method for all known impurities 
was determined by analyzing lopinavir and ritonavir 
sample solutions spiked with all the known substances at 
three different concentration levels of 50, 100 and 150% 
of each in triplicate at the specified limit at LOQ and 
reference level. The recovery of all known substances were 
found to be in-between the predeﬁned acceptance criterion 
of 89.61 to 108.22% and the data is given in Table III.
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Robustness
The robustness of the method was studied by small 
but deliberate changes to mobile phase flow, column oven 
temperature and pH. The effects of these changes were 
tested on the drug spiked with reference solution. The 
parameters selected were pH of the mobile phase (±0.2 
units), flow rate (±0.1 mL/min), and column temperature 
(±2 oC). Only one parameter was changed while the others 
were kept unaltered. The difference between robustness 
values from the actual optimized condition results was 
found to be below 10.0%. The studies indicated that there 
was no effect on the determination of related substances 
and the selectivity. Therefore, the test method was robust 
for the quantiﬁcation of related substances.
CONCLUSION
The proposed method is simple, rapid and selective. 
Percent Relative standard Deviation was very low, below 
2.0%, which indicate that the method is highly precise. 
Short Analysis time (≤12 min) coupled with simplicity and 
ease of operation warrants use of the method for analysis of 
lopinavir, ritonavir and its known impurities stated above in 
Bulk as well as in Formulated dosages for Assays and for 
said known impurities by UPLC. Therefore, the method can 
be useful in routine quality Control analysis in bulk.
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